Menu
← Oncology Approval Tracker
FDA DECISION ·
Idelalisib tablets
idelalisib · Natco Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic of Zydelig tablets with rituximab for relapsed CLL in patients for whom comorbidities make rituximab alone an appropriate option.
LAMPGEN ANALYSIS
Why it matters
This generic action applies to a defined relapsed CLL population. The comorbidity criterion matters when explaining how the combination is used.
What research teams should watch
Check the reference and generic label for the selected use and confirm pharmacy availability. Maintain monitoring for the established regimen’s safety risks.
PRIMARY RECORDS